Insights

Growth trajectory Everest Medicines demonstrates rapid revenue growth with a six-month revenue of RMB 1,147.8 million (approximately $170 million) in 2026, up about 157% year over year, signaling robust demand and expanding market reach in Greater China that sales teams can target with partnered manufacturing, licensing, or co-development opportunities.

Strategic partnerships The company actively pursues and secures exclusive rights for assets in Greater China and select Southeast Asian markets, such as DMX-200 for FSGS, highlighting a willingness to form strategic alliances that can be leveraged for joint commercialization, regional distribution, and local regulatory navigation.

Robust R&D focus Recent leadership appointments to strengthen mRNA and translational sciences capabilities, coupled with AI-driven oncology vaccine and CAR-T programs, indicate a strong pipeline modernization. This creates opportunities to offer specialized CRO/CMC support, translational services, and platform collaborations.

People & credibility Recognition as a Top Employer in China and a seasoned team with deep clinical development and regulatory expertise enhance credibility for partner discussions, making Everest Medicines a compelling co-development or contract manufacturing partner for global innovators seeking local market access.

Market expansion With a Series A endorsement from a leading China healthcare PE and a focus on mainland China and Asian territories, Everest Medicines is positioned to expand beyond existing products, presenting opportunities for regional commercialization, distribution agreements, and market-entry collaborations with global pharma companies seeking Asia-Pacific footprints.

Similar companies to Everest Medicines

Everest Medicines Tech Stack

Everest Medicines uses 8 technology products and services including Power BI, Amazon Web Services, WordPress, and more. Explore Everest Medicines's tech stack below.

Media & News

Everest Medicines's Email Address Formats

Everest Medicines uses at least 2 email formats:
Everest Medicines Email FormatsExamplePercentage
First.Last@everestmedicines.comJohn.Doe@everestmedicines.com
98%
Last.F@everestmedicines.comDoe.J@everestmedicines.com
2%

Frequently Asked Questions

What is Everest Medicines's official website and social media links?

Minus sign iconPlus sign icon
Everest Medicines's official website is everestmedicines.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Everest Medicines generate?

Minus sign iconPlus sign icon
As of October 2026, Everest Medicines's annual revenue is estimated to be $250M - $500M.

What is Everest Medicines's NAICS code?

Minus sign iconPlus sign icon
Everest Medicines's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Everest Medicines have currently?

Minus sign iconPlus sign icon
As of October 2026, Everest Medicines has approximately 152 employees across 2 continents, including Asia and North America. Key team members include Ceo: R. L., Chief Scientific Officer: J. Y. and Vice President Head Of Legal & Compliance: C. T. Explore Everest Medicines's employee directory with LeadIQ.

What industry does Everest Medicines belong to?

Minus sign iconPlus sign icon
Everest Medicines operates in the Pharmaceutical Manufacturing industry.

What technology does Everest Medicines use?

Minus sign iconPlus sign icon
Everest Medicines's tech stack includes Power BI, Amazon Web Services, WordPress, SAP, Zoho, Microsoft 365, Microsoft Azure and VMware.

What is Everest Medicines's email format?

Minus sign iconPlus sign icon
Everest Medicines's email format typically follows the pattern of First.Last@everestmedicines.com. Find more Everest Medicines email formats with LeadIQ.

How much funding has Everest Medicines raised to date?

Minus sign iconPlus sign icon
As of October 2026, Everest Medicines has raised $517M in funding. The last funding round occurred on May 14, 2026 for $310M.
Everest Medicines logo

Everest Medicines

Pharmaceutical ManufacturingNew York, United States51-200 Employees

Everest Medicines is a mid-sized pharmaceutical company based in New York City, New York. It concentrates on developing and marketing therapies for patients in mainland China and other parts of Asia. The company aims to partner with global innovators to bring medicines to the Greater China market and to pursue products with a high probability of regulatory approval.

Its team has experience in clinical development, regulatory affairs, CMC, and operations in China and in collaborations with international pharmaceutical firms. In June 2026, Everest Medicines announced an exclusive Asia-Pacific licensing arrangement with Jiangsu Vcare PharmaTech Co., Ltd to develop, register, and commercialize Sumecigrel across multiple Asia-Pacific markets, including Southeast Asia, South Korea, Australia, Hong Kong, Macau, and Taiwan.

Section iconCompany Overview

NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Employees
51-200

Section iconFunding & Financials

  • $517M

    Everest Medicines has raised a total of $517M of funding over 3 rounds. Their latest funding round was raised on May 14, 2026 in the amount of $310M as a Post IPO Secondary.

  • $250M - $500M

    Everest Medicines's revenue is estimated to be in the range of $250M - $500M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.